Sage Therapeutics has a unique approach to targeting GABA, which allows it to target CNS disorders. Read why I think SAGE ...

Sage Therapeutics' financials indicate a need for additional funding in 2025, risking dilution and further financial ...

Sage Therapeutics Inc. (NASDAQ:SAGE) confirmed that Biogen Inc. (NASDAQ:BIIB) submitted an unsolicited, nonbinding proposal ...

Sage Therapeutics has brought a lawsuit against Biogen shortly after receiving an “unsolicited” offer from its neuroscience ...

Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE – Get Free Report) have been assigned a consensus rating of “Hold” from the ...

RBC Capital analyst Brian Abrahams maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report) on January 21 and set a price target ...

In a report released today, George Farmer from Scotiabank maintained a Buy rating on SAGE Therapeutics (SAGE – Research Report), with a price ...

Sage Therapeutics (SAGE) witnessed a jump in share price last session on above-average trading volume. The latest trend in ...

Biogen’s effort to buy Sage reveals its “desire to expand its pipeline at a discount,” according to analysts from BMO Capital ...

( MENAFN - GlobeNewsWire - Nasdaq) NEW YORK, Jan. 24, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Sage ...

Today's sure has SAGE on track for its largest single-day percentage gain since January 2019. Though further removed from ...

Sage Therapeutics, Inc. (Nasdaq: SAGE) saw its stock price soar by an impressive 33.87%, reaching $7.43 during Monday’s premarket trading session. The surge came on the heels of the company’s ...